We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+85.72%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$73.2M
Cap. Flow
-$340M
Cap. Flow %
-27.05%
Top 10 Hldgs %
36.58%
Holding
220
New
69
Increased
26
Reduced
46
Closed
56

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$13.6M
2
GOSS icon
Gossamer Bio
GOSS
+$8.85M
3
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$7.61M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.3M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$6.53M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$23.1M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$17.3M
3
IMVT icon
Immunovant
IMVT
+$12M
4
ARGX icon
argenx
ARGX
+$11.4M
5
VSTM icon
Verastem
VSTM
+$7.36M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
151
AnaptysBio
ANAB
$1.54B
$102K 0.01%
+4,581
New +$83.7K
CLVS
152
DELISTED
Clovis Oncology, Inc.
CLVS
$101K 0.01%
14,918
-397,000
-96% -$3.01M
CSCI
153
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$94K 0.01%
1,174
– –
INSM icon
154
Insmed
INSM
$22.4B
$80K 0.01%
2,919
-170,000
-98% -$4.03M
DTIL icon
155
Precision BioSciences
DTIL
$178M
$73K 0.01%
+294
New +$64.4K
APLS
156
DELISTED
Apellis Pharmaceuticals
APLS
$69K 0.01%
2,126
-50,000
-96% -$1.61M
MITO
157
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
$69K 0.01%
37,597
– –
DNTH icon
158
Dianthus Therapeutics
DNTH
$5.69B
$65K 0.01%
+542
New +$76.4K
XFOR icon
159
X4 Pharmaceuticals
XFOR
$377M
$47K ﹤0.01%
+167
New +$45.7K
ALPN
160
DELISTED
Alpine Immune Sciences Inc
ALPN
$46K ﹤0.01%
+4,739
New +$20.5K
VIRX
161
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$29K ﹤0.01%
3,184
– –
VKTX icon
162
Viking Therapeutics
VKTX
$3.88B
$8K ﹤0.01%
1,159
-125,000
-99% -$830K
ABBV icon
163
CALL
AbbVie
ABBV
$465B
– –
-150,000
Closed -$11.4M
ACAD icon
164
CALL
Acadia Pharmaceuticals
ACAD
$4.51B
– –
-150,000
Closed -$6.34M
ALLK
165
CALL
DELISTED
Allakos
ALLK
– –
-30,000
Closed -$1.33M
ALLK
166
PUT
DELISTED
Allakos
ALLK
– –
-30,000
Closed -$1.33M
ALNY icon
167
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
– –
-246,900
Closed -$26.9M
ALNY icon
168
PUT
Alnylam Pharmaceuticals
ALNY
$38.3B
– –
-120,300
Closed -$13.1M
AMRN
169
CALL
Amarin Corp
AMRN
$297M
– –
-1,985
Closed -$159K
ARGX icon
170
CALL
argenx
ARGX
$55.2B
– –
-75,000
Closed -$9.88M
ARWR icon
171
PUT
Arrowhead Research
ARWR
$12.1B
– –
-7,200
Closed -$207K
ASMB icon
172
PUT
Assembly Biosciences
ASMB
$498M
– –
-12,500
Closed -$2.23M
ASND icon
173
PUT
Ascendis Pharma A/S
ASND
$16.5B
– –
-70,000
Closed -$3.76M
AUPH icon
174
PUT
Aurinia Pharmaceuticals
AUPH
$1.95B
– –
-100,000
Closed -$1.45M
AVDL
175
CALL
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-750,000
Closed -$5.96M
5 6
7
8 9

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Ikarian Capital held 220 positions worth $1.26B, down 5.5% from $1.33B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Ikarian Capital withdrew a net $340M in Q2 2020, closing 56 positions and reducing 46 holdings. Its most notable exit was Acceleron Pharma, an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 20% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Blueprint Medicines worth $15.7M.

  • Ikarian Capital's largest Q2 2020 buy was Blueprint Medicines: 201,662 shares worth $15.7M.
  • Ikarian Capital added most to bluebird bio in Q2 2020, an estimated $5.73M increase.
  • Ikarian Capital's biggest Q2 2020 reduction was BioXcel Therapeutics, cutting an estimated $17.3M.
  • Ikarian Capital fully exited Acceleron Pharma in Q2 2020, selling an estimated $23.1M.
  • Ikarian Capital's ten largest holdings make up 37% of its $1.26B portfolio in Q2 2020.
  • Ikarian Capital opened 69 new positions and closed 56 in Q2 2020.
  • Ikarian Capital's portfolio value fell 5.5% quarter-over-quarter to $1.26B.

Based on Ikarian Capital's 13F filing for Q2 2020, filed 14 Aug 2020.